SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...
CASTRES, France & BOSTON--(BUSINESS WIRE)--Pierre Fabre Laboratories, a global player in oncology, and Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated ...
Biomarker Therapy in 2025: More Lung Cancer Options, Competition in New Drug Classes, ctDNA Advances
This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing evidence on the utility of ctDNA testing.
NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile Zidesamtinib shown to be ...
Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapy ALPACCA pivotal trial is designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback